Oncology and Hematology - Global Oncology Academy

Episodes 65-80 of 105

What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
CME/CE
Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
1.00 credit
- James M. Cleary, MD, PhD
- Kathleen Madden, FNP, MSN, AOCNP, APHN
1.00 credit
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
CME/CE
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
0.25 credits
- Jonathan D. Schoenfeld, MD, MPhil, MPH
- Robert L. Ferris, MD, PhD
0.25 credits
Accelerating Evidence-Based Care in LA SCCHN
Accelerating Evidence-Based Care in LA SCCHN
CME/CE
Accelerating Evidence-Based Care in LA SCCHN
0.25 credits
- Ezra Cohen, MD, FRCPSC, FASCO
- Sue S. Yom, MD, PhD
0.25 credits
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
MinuteCE®
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
0.75 program credits
- Christopher M. Gallagher, MD
0.75 program credits
MinuteCE®
RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer
0.75 credits 7 episodes
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 credits 7 episodes
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
MinuteCE®
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
0.75 program credits
- Adam Brufsky, MD, PhD
0.75 program credits
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
MinuteCE®
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
0.75 program credits
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 program credits
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
MinuteCE®
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
0.75 program credits
- Christopher M. Gallagher, MD
0.75 program credits
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
MinuteCE®
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
0.75 program credits
- Adam Brufsky, MD, PhD
0.75 program credits
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
MinuteCE®
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
0.75 program credits
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 program credits
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
MinuteCE®
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
0.75 program credits
- Christopher M. Gallagher, MD
- Adam Brufsky, MD, PhD
0.75 program credits
Case Study: Treatment Sequencing in Platinum-Sensitive Relapse ES-SCLC
Case Study: Treatment Sequencing in Platinum-Sensitive Relapse ES-SCLC
MinuteCE®
Case Study: Treatment Sequencing in Platinum-Sensitive Relapse ES-SCLC
1.50 program credits
- Ticiana Leal, MD
- Jacob Sands, MD
1.50 program credits

5/7